Mechanisms |
Signalling pathways/Targets |
Signalling pathways/Targets |
Solutions |
References |
AR reactivation |
AR enhancer (650 kb centromeric) |
|
|
(Takeda, Spisák et al., 2018) |
|
Galectin-3 |
|
|
(Dondoo, Fukumori et al., 2017) |
|
BMI1 |
PTC209 (BMI1 inhibitor) |
PTC209 (BMI1 inhibitor) |
(Zhu, Zhao
et al., 2018) |
|
FOXA1/CREB5/AR |
|
|
(Hwang, Seo et al., 2019) |
|
IKBKE/Hippo/c-Myc/AR |
|
|
(Bainbridge, Walker et al.,
2020) |
|
EphB4/c-Myc/AR |
EphB4 inhibitors |
EphB4 inhibitors |
(Li, Lanman et
al., 2020) |
|
eIF4F |
|
|
(Liu, Horn et al., 2019) |
|
STAT3/AR |
GPA500 |
GPA500 |
(Thaper, Vahid et al.,
2018) |
|
AR/AR-Vs |
Triptolide |
Triptolide |
(Han, Huang et al.,
2017) |
|
AR |
Tetraaryl cyclobutane (CBs) |
Tetraaryl cyclobutane (CBs) |
(Pollock, Wardell et al., 2016) |
|
AR |
ARCC-4/UT-34/IRF8 |
ARCC-4/UT-34/IRF8 |
(Salami, Alabi et al.,
2018) |
AR splice variants |
lncRNA Malat1 |
|
|
(Tummala, Lou et al.,
2017; Stone, 2017; Zhao, Wang et al., 2018) |
|
ACK1/pY88-H4/WDR5/MLL2/AR, AR-V7 |
|
|
(Mahajan, Malla et al.,
2017) |
|
AR-V7 |
SPT |
SPT |
(Lam, Nguyen et al., 2020) |
|
AVPR1A |
|
|
(Zhao, Peacock et al., 2019) |
|
NK cells/microRNA-34, microRNA-449/AR-V7, EZH2 |
|
|
(Lin, Chou et
al., 2017) |
|
HSP70/STUB1/AR-V7 |
|
|
(Liu, Lou et al., 2018) |
|
AKR1C3/AR-V7 |
|
|
(Liu, Yang et
al., 2019) |
|
AR-V7 |
ABT263 (BCL2 protein inhibitor)/IPI-9119 (fatty acid synthase
inhibitor)/Luteolin/CDDO-Me/Degarelix |
ABT263 (BCL2 protein
inhibitor)/IPI-9119 (fatty acid synthase
inhibitor)/Luteolin/CDDO-Me/Degarelix |
(Zadra, Ribeiro et al., 2019;
Naiki-Ito, Naiki et al., 2019; Khurana, Chandra et al., 2020; Cucchiara,
Yang et al., 2019) |
|
c-Myc/AR-Vs, AR-FL |
Quiflapon (5-Lox inhibitor) |
Quiflapon (5-Lox
inhibitor) |
(BaiCao et al., 2019; Monga, Subramani et al.,
2020) |
|
GATA2/AR-FL, AR-Vs |
|
|
(Chaytor, Simcock et al.,
2019) |
|
BRD4 |
JQI/I-BET762 (BET inhibitors) |
JQI/I-BET762 (BET inhibitors) |
(Asangani, Dommeti et al., 2014; Chan, Selth et al.,
2015) |
|
ZFX/AR-V7 |
|
|
(Cai, Tsai et al., 2018) |
|
PARP/AR-V7 |
|
|
(Kounatidou, Nakjang et al., 2019) |
AR mutations |
AR F876L mutation |
ASC-J9®/JJ-450 |
ASC-J9®/JJ-450 |
(Joseph, Lu et al., 2013; Korpal, Korn et al., 2013;
Wang, Lin et al., 2016) |
|
F877L, H875Y, T878A/D891H, and T878A/S889G |
ODM-201 |
ODM-201 |
(Prekovicvan Royen et al., 2016; Borgmann, Lallous et al., 2018;
LallousVolik et al., 2016) |
GR overexpression |
AMFR-11β-HSD2 |
|
|
(Li, Alyamani et al.,
2017) |
|
TLE3 |
|
|
(Palit, Vis et al., 2019) |
|
PI3K/AKT/GR |
|
|
(Adelaiye-Ogala, Gryder et al., 2020) |
|
GR/AR |
Z19 (GR/AR dual antagonist) |
Z19 (GR/AR dual antagonist) |
(Wu, Xie et al., 2019) |